Insider · CIK 0001985496
Weiguo Ye
Files at GYRE (GYRE THERAPEUTICS, INC.). First filing May 18, 2026, latest Jun 22, 2026.
In brief
Weiguo Ye files SEC Form 4 as COO at GYRE (GYRE THERAPEUTICS, INC.). Since May 18, 2026, Weiguo Ye has reported 0 open-market buys worth $0 and 8 open-market sells worth $870k, the latest filed on Jun 22, 2026.
A track record needs three past buys with six months of prices behind them; Weiguo Ye has 0, so none is measured yet.
The newest scored trade: sold $69k of GYRE on Jun 9, 2026, filed Jun 22, 2026, scored 13 (weak). In the last 12 months: 0 buys worth $0 and 8 sells worth $870k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GYRE: GYRE THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | GYREsell GYRE THERAPEUTICS, INC. | $69k 11,000 shares | -2% | +10% from low-32% from high | |
| 5Weak | GYREsell GYRE THERAPEUTICS, INC. | $17k 2,800 shares | -0% | +9% from low-32% from high | |
| 16Weak | GYREsell GYRE THERAPEUTICS, INC. | $129k 20,918 shares | -3% | +10% from low-32% from high | |
| 17Weak | GYREsell GYRE THERAPEUTICS, INC. | $219k 34,976 shares | -5% | +11% from low-31% from high | |
| 11Weak | GYREsell GYRE THERAPEUTICS, INC. | $46k 7,500 shares | -1% | +0% from low-46% from high | |
| 16Weak | GYREsell GYRE THERAPEUTICS, INC. | $137k 22,220 shares | -3% | 0% from low-47% from high | |
| 20Weak | GYRE THERAPEUTICS, INC. | $59k 9,320 shares | -1% | 0% from low-44% from high | |
| 25Weak | GYRE THERAPEUTICS, INC. | $195k 28,680 shares | -4% | +5% from low-39% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 11, 2026 | GYRE GYRE THERAPEUTICS, INC. | 300,000 0.33% of outstanding | $2.1M | May 13, 2026 | none |
| Nov 13, 2025 | GYRE GYRE THERAPEUTICS, INC. | 548,000 0.57% of outstanding | $4.6M | Nov 15, 2025 | none |
Transactions
The newest 50 of 57 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +3,000 | $0.75 | $2,250 | 703,000 | Jun 22, 2026 |
| Jun 9, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -3,000 | $6.15 | $18k | 700,000 | Jun 22, 2026 |
| Jun 10, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +5,000 | $0.75 | $3,750 | 705,000 | Jun 22, 2026 |
| Jun 10, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -5,000 | $6.24 | $31k | 700,000 | Jun 22, 2026 |
| Jun 18, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +3,000 | $0.75 | $2,250 | 703,000 | Jun 22, 2026 |
| Jun 18, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -3,000 | $6.35 | $19k | 700,000 | Jun 22, 2026 |
| Jun 9, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -3,000 | $0.00 | $0 | 835,701 | Jun 22, 2026 |
| Jun 10, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 830,701 | Jun 22, 2026 |
| Jun 18, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -3,000 | $0.00 | $0 | 827,701 | Jun 22, 2026 |
| Jun 11, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +2,800 | $0.75 | $2,100 | 702,800 | Jun 15, 2026 |
| Jun 11, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -2,800 | $6.17 | $17k | 700,000 | Jun 15, 2026 |
| Jun 11, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -2,800 | $0.00 | $0 | 838,701 | Jun 15, 2026 |
| Jun 9, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +14,500 | $0.75 | $11k | 714,500 | Jun 11, 2026 |
| Jun 9, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -14,500 | $6.14 | $89k | 700,000 | Jun 11, 2026 |
| Jun 10, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +6,418 | $0.75 | $4,814 | 706,418 | Jun 11, 2026 |
| Jun 10, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -6,418 | $6.21 | $40k | 700,000 | Jun 11, 2026 |
| Jun 9, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -14,500 | $0.00 | $0 | 847,919 | Jun 11, 2026 |
| Jun 10, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -6,418 | $0.00 | $0 | 841,501 | Jun 11, 2026 |
| Jun 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +19,575 | $0.75 | $15k | 719,575 | Jun 8, 2026 |
| Jun 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -19,575 | $6.13 | $120k | 700,000 | Jun 8, 2026 |
| Jun 5, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +15,401 | $0.75 | $12k | 715,401 | Jun 8, 2026 |
| Jun 5, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -15,401 | $6.40 | $99k | 700,000 | Jun 8, 2026 |
| Jun 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -19,575 | $0.00 | $0 | 877,820 | Jun 8, 2026 |
| Jun 5, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -15,401 | $0.00 | $0 | 862,419 | Jun 8, 2026 |
| May 22, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +3,500 | $0.75 | $2,625 | 703,500 | May 27, 2026 |
| May 22, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -3,500 | $6.08 | $21k | 700,000 | May 27, 2026 |
| May 26, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +4,000 | $0.75 | $3,000 | 704,000 | May 27, 2026 |
| May 26, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -4,000 | $6.10 | $24k | 700,000 | May 27, 2026 |
| May 22, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -3,500 | $0.00 | $0 | 901,395 | May 27, 2026 |
| May 26, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -4,000 | $0.00 | $0 | 897,395 | May 27, 2026 |
| May 20, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +9,400 | $0.75 | $7,050 | 709,400 | May 22, 2026 |
| May 20, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -9,400 | $6.15 | $58k | 700,000 | May 22, 2026 |
| May 21, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +12,820 | $0.75 | $9,615 | 712,820 | May 22, 2026 |
| May 21, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -12,820 | $6.15 | $79k | 700,000 | May 22, 2026 |
| May 20, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -9,400 | $0.00 | $0 | 917,715 | May 22, 2026 |
| May 21, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -12,820 | $0.00 | $0 | 904,895 | May 22, 2026 |
| May 18, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +200 | $0.75 | $150 | 700,200 | May 20, 2026 |
| May 18, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -200 | $6.62 | $1,324 | 700,000 | May 20, 2026 |
| May 19, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +9,120 | $0.75 | $6,840 | 709,120 | May 20, 2026 |
| May 19, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -9,120 | $6.37 | $58k | 700,000 | May 20, 2026 |
| May 18, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -200 | $0.00 | $0 | 936,235 | May 20, 2026 |
| May 19, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -9,120 | $0.00 | $0 | 927,115 | May 20, 2026 |
| May 14, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +15,580 | $0.75 | $12k | 715,580 | May 18, 2026 |
| May 14, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -15,580 | $6.91 | $108k | 700,000 | May 18, 2026 |
| May 15, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +13,100 | $0.75 | $9,825 | 713,100 | May 18, 2026 |
| May 15, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stock | -13,100 | $6.65 | $87k | 700,000 | May 18, 2026 |
| May 14, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -15,580 | $0.00 | $0 | 949,535 | May 18, 2026 |
| May 15, 2026 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -13,100 | $0.00 | $0 | 936,435 | May 18, 2026 |
| Apr 1, 2025 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Common Stock | +50,000 | $0.75 | $38k | 700,000 | May 14, 2025 |
| Apr 1, 2025 | GYRE GYRE THERAPEUTICS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 965,115 | May 14, 2025 |
Questions about Weiguo Ye
Answered from the filings on this page, as of the latest one.
Is Weiguo Ye buying or selling?
In the last 12 months Weiguo Ye reported 0 open-market buys worth $0 and 8 open-market sells worth $870k on SEC Form 4; the latest was sold $69k of GYRE on Jun 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Weiguo Ye's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Weiguo Ye has 0.
Where does Weiguo Ye file Form 4?
Weiguo Ye has filed Form 4 at GYRE (GYRE THERAPEUTICS, INC.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.